Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by CANbridge Pharmaceuticals Inc.

CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge and UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy (CAN203) Improves Lifespan and Motor Function in Mice When Administered via Intracerebroventricular Injection
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge-UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy Animal Data to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress
From CANbridge Pharmaceuticals Inc.
Via Business Wire
First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2 Trial for the Treatment of Gaucher Disease in China
From CANbridge Pharmaceuticals Inc.
Via Business Wire
First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Appoints Industry Leader Edward Hu to the Board
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2022
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals to Participate in the Morgan Stanley Virtual China Summit 2022
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals CAN108 New Drug Application (NDA) for Alagille Syndrome Accepted by China’s National Medical Products Administration
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals Enters into Duchenne Muscular Dystrophy Gene Therapy Research Agreement with University of Washington School of Medicine
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)
From CANbridge Pharmaceuticals Inc.
Via Business Wire
CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms
From CANbridge Pharmaceuticals Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.